MAPT and Alzheimer disease: Wang et al. (2016) found that intramuscular delivery of AAV-p75ECD increased the levels of p75ECD in the blood, significantly improving the behavioral phenotype of APP/PS1 transgenic mice, reducing brain amyloid burden, decreasing tau hyperphosphorylation, and attenuating neuroinflammation. Another study found that inducing the AD-like phenotype in normal mice via MST1, and knocking down or chemically inactivating MST1 significantly improved cognitive deficits and neuronal apoptosis in 7-month-old 5xFAD mice (Wang et al., 2022) (Table 2).